Duncker Streett & Co. Inc. lifted its stake in Celgene Co. (NASDAQ:CELG) by 15.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 12,185 shares of the biopharmaceutical company’s stock after purchasing an additional 1,640 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Celgene were worth $1,272,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of CELG. Janus Henderson Group PLC increased its stake in Celgene by 4,290.5% during the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after acquiring an additional 8,217,433 shares during the last quarter. BlackRock Inc. increased its stake in Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after acquiring an additional 3,084,227 shares during the last quarter. Oaktop Capital Management II L.P. acquired a new stake in Celgene during the second quarter worth $271,605,000. Arrowstreet Capital Limited Partnership increased its stake in Celgene by 1,489.2% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after acquiring an additional 1,787,052 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after acquiring an additional 1,610,056 shares during the last quarter. 77.84% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have issued reports on the company. UBS Group cut Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 target price for the company. in a research note on Thursday, October 26th. Wells Fargo & Co cut Celgene from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 26th. Cann reissued a “buy” rating on shares of Celgene in a research note on Thursday, October 26th. Cantor Fitzgerald set a $162.00 target price on Celgene and gave the stock a “buy” rating in a research note on Thursday, October 26th. Finally, Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 target price for the company. in a research note on Monday, December 18th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $130.25.
Celgene Co. (CELG) opened at $93.89 on Thursday. The stock has a market capitalization of $70,591.68, a price-to-earnings ratio of 26.23, a P/E/G ratio of 0.66 and a beta of 1.49. Celgene Co. has a fifty-two week low of $88.32 and a fifty-two week high of $147.17. The company has a quick ratio of 4.80, a current ratio of 4.99 and a debt-to-equity ratio of 2.29.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.78 by $0.09. The firm had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. Celgene’s revenue was up 16.9% compared to the same quarter last year. During the same period last year, the business posted $1.61 earnings per share. research analysts anticipate that Celgene Co. will post 7.68 EPS for the current year.
Celgene declared that its board has initiated a share buyback plan on Wednesday, February 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its stock is undervalued.
In related news, insider Mark J. Alles bought 3,260 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was purchased at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the acquisition, the insider now owns 178,904 shares in the company, valued at approximately $16,441,277.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $95.99, for a total value of $887,907.50. Following the completion of the transaction, the director now owns 94,801 shares of the company’s stock, valued at $9,099,947.99. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/02/22/duncker-streett-co-inc-buys-1640-shares-of-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.